Search for a trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

This study has been transitioned to CTIS with ID 2024-511967-26-00 check the CTIS register for the current data. Primary Objective: The primary objective is to evaluate the efficacy of daratumumab plus CyBorD compared with CyBorDalone in the…

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-507143-11-00 check the CTIS register for the current data. Primary objective: To determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (…